Calcific aortic valve disease is a progressive fibrocalcific process that can only be treated with valve replacement. Cadherin-11 has recently been identified as a potential therapeutic target for calcific aortic valve disease. The already approved drug celecoxib, a cyclooxygenase-2 inhibitor, binds cadherin-11, and was investigated as a therapeutic against calcific aortic valve disease. Unexpectedly, celecoxib treatment led to hallmarks of myofibroblast activation and calcific nodule formation in vitro. Retrospective electronic medical record analysis of celecoxib, ibuprofen, and naproxen revealed a unique association of celecoxib use and aortic stenosis.
CITATION STYLE
Bowler, M. A., Raddatz, M. A., Johnson, C. L., Lindman, B. R., & Merryman, W. D. (2019, April 1). Celecoxib Is Associated With Dystrophic Calcification and Aortic Valve Stenosis. JACC: Basic to Translational Science. Elsevier Inc. https://doi.org/10.1016/j.jacbts.2018.12.003
Mendeley helps you to discover research relevant for your work.